Please login to the form below

How to nail pre-launch positioning in Pharma

Head of Commercial Matt Bolton lays out three key points for getting your pre-launch positioning right in Pharma and healthcare.
Marketing strategy is core to what we do at Blue Latitude, and we’ve been increasingly involved in launching pharma products across various therapy areas. Recently, we’ve worked across multiple brands in oncology on launch and pre-launch strategy, which raises a unique set of challenges in a competitive and highly regulated market.

A recent project focussed on early stages pre-launch strategy, which means looking at positioning rather than messaging. At this stage, it’s important to understand the disease area and unmet patient needs in the wider market. Our client was facing some key issues that were particularly challenging in a highly competitive market (before final clinical data is available) –  demonstrating value without using cost or medical claims as primary differentiator, and establishing the relevance of lower level clinical end points. Matt Bolton, Head of Commercial, takes us through the three key points to keep in mind when facing a similar situation.

Read the full article here: http://engage.bluelatitude.net/pre-launch-positioning-pharma



7th August 2015

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Diagnosing the lag in neuropsychiatric treatments
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
Blue Latitude Health
Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
Blue Latitude Health
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Blue Latitude Health
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.
Blue Latitude Health
Battling breast cancer with precision medicine (Part 1)
Laura Holmes Haddad is a breast cancer survivor. She made the incredibly brave decision to participate in a PARP inhibitor precision medicine trial. Here, the author and precision medicine advocate tells her story and explains what industry needs to remember when treating cancer patients with precision medicine.
Blue Latitude Health
The role of brain health in treating MS
Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the importance of a holistic approach to MS and why digital technology is the future of effective MS care.
Blue Latitude Health